Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.…
OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand
Curatis Holding (SWX: CURN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 15.75 CHF on 20 November 2026, up 29.1% over 52 weeks. Its 52-week range is 11.05 CHF to 27.90 CHF: the price is 43.5% below the high and 42.5% above the low.
Its market capitalisation is 83.69M CHF.
Curatis Holding reports return on equity of -3.1%, an operating margin of -4.8% and revenue up 51.4% year over year.
It holds more cash than debt, a net cash position of 3.60M CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.